Home > Pharmaceuticals >  Ophthalmology >  Glaucoma: Competitive Landscape to 2026

Glaucoma: Competitive Landscape to 2026

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. In glaucoma patients, the IOP—the normal healthy eye pressure that is achieved when the eye produces a small amount of aqueous humor while letting an equal amount of fluid out of the eye—is disturbed due to mechanical compression and/or decreased blood flow to the optic nerve, thereby leading to increased IOP. This increased IOP damages the optic nerve fibers that send signals from the retina to the brain, resulting in blind spots in the vision field when a significant number of nerve fibers are damaged, and blindness when the entire nerve is destroyed. The exact cause of optic nerve damage from glaucoma is not yet clearly.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. Overall, GlobalData expects new drug approvals to drive Glaucoma market growth over the next decade (2016–2026).


GlobalData’s Glaucoma: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies Mentioned

Aerie Pharmaceutical

Ocular Therapeutix


Santen Pharmaceutical

Neurotech Pharmaeutical

Isarna Therapeutics

Senju Pharmaceutical

Wakamoto Pharmaceutical

Envisia Therapeutics

Lee’s Pharmaceutical






Bausch + Lomb

Otsuka Pharmaceutical

Merck & Co.


ForSight VISION5

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview and Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in Glaucoma

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan and China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports